Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Physical examination, 12-lead electrocardiogram assessment, SERETIDE delivered via a capsule-based inhaler
SERETIDE Rotacaps · 2 trials · 1 indication
Area under the plasma fluticasone propionate concentration-time curve over dosing interval; maximum concentration for fluticasone propionate and salmeterol plasma concentration-time curve on the last day of each study treatment period (Day 4).
Blood samples of participants (par.) with asthma and chronic obstructive pulmonary disease (COPD) were collected and analyzed for AUC(0-tau), a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). Asthma is a disorder that causes the airways of the lungs to swell and narrow, leading to difficulty in breathing. COPD is a chronic lung disease with structural changes in lungs, leading to difficulty in breathing.
Participants' blood samples were collected and analyzed for SC levels. Weighted mean SC levels are evaluted as a measure of the degree of cortisol suppression, allowing for the determination of whether differences in systemic exposure to the inhaled steroid component of two devices can be significant enough to result in the differences in the body's ability to release cortisol. Weighted means were derived by calculating the AUC over the 0-12 hour period, using the linear trapezoidal rule (statistical technique used for numerical analysis) and then dividing it by the actual time interval.
| Arm | Type | Description |
|---|---|---|
| SERETIDE Rotacaps | EXPERIMENTAL | Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a capsule-based inhaler (Rotahaler). Devices with varying airflow resistance, low, intermediate and high, will be used. |
| SERETIDE Diskus | ACTIVE_COMPARATOR | Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a multi-dose dry powder inhaler |
| Placebo Rotacaps | PLACEBO_COMPARATOR | Placebo delivered in a capsule-based inhaler |
| Placebo Diskus | PLACEBO_COMPARATOR | Placebo delivered in a multi-dose dry powder inhaler |
| Name | Type | Description |
|---|---|---|
| SERETIDE Rotacaps | DRUG | The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4. |
| SERETIDE Diskus | DRUG | The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4. |
INCLUSION CRITERIA: A subject will be eligible for inclusion in this study only if all of the following criteria apply: * ALT, alkaline phosphatase and bilirubin less than or equal to 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Si...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
SERETIDE Rotacaps is an inhaled asthma treatment that combines fluticasone propionate and salmeterol in a capsule-based dry powder formulation delivered with the ROTAHALER device. It is being studied in patients with asthma, including moderate asthma, and in patients with moderate to severe chronic obstructive pulmonary disease.
SERETIDE Rotacaps is developed by GSK plc, which trades under the ticker GSK. GSK conducted the clinical studies of the fluticasone propionate and salmeterol combination delivered through the ROTAHALER device.
SERETIDE Rotacaps is in Phase 1 clinical development. Both of its recorded trials are Phase 1 studies, and both have been completed. It is an investigational product and is not described as approved.
Two completed Phase 1 trials cover SERETIDE Rotacaps. NCT01540708 studied healthy volunteers in Australia to optimize the Rotacap formulation and ROTAHALER device. NCT01494610 was a pharmacokinetic and pharmacodynamic study in moderate asthma and moderate to severe COPD patients in Australia and New Zealand. Together they enrolled 96 participants.
Both SERETIDE Rotacaps trials were randomized, double-blind, and actively controlled. NCT01540708 enrolled 36 healthy volunteers aged 18 and older in Australia. NCT01494610 enrolled 60 participants aged 18 and older with moderate asthma or moderate to severe COPD across Australia and New Zealand.
SERETIDE Rotacaps delivers a combination of fluticasone propionate and salmeterol as a small molecule treatment in a capsule-based dry powder inhaler. The formulation is paired with the ROTAHALER device, and one trial specifically examined optimizing that Rotacap formulation and device for delivery.